The current portfolio environment offers no company that shows a sufficiently strong alignment across all five analysis levels of the RED HOT CHILI™ MUMAK.
Why the RED HOT CHILI™ MUMAK is not being awarded this week
With the RED HOT CHILI™ MUMAK, we recognize the company that currently shows the strongest alignment across our five analysis levels:
- Geopolitics
- Industry
- Fundamentals
- News & Market Sentiment
- Technical Analysis
This week, none of the companies in the UMBRELLA Strategy convincingly meet these requirements.
The UMBRELLA Strategy continues to include several companies with constructive long-term prospects. However, short-term momentum is mixed, and technical signals are not consistently supportive.
Revolution Medicines comes closest to an award
Revolution Medicines is currently the position with the strongest performance in the portfolio. Since its inclusion, it has recorded a price gain of around 26.1% and has a weighting of approximately 18.2%.
The company also received another Breakthrough Therapy designation from the FDA for RASONQUE (Daraxonrasib), this time in combination with chemotherapy for the first-line treatment of metastatic pancreatic cancer.
However, the positive development has already been accompanied by a significant price increase. Revolution Medicines therefore remains a company that should continue to be closely monitored.
Micron cannot confirm last week’s momentum
Micron Technology received the RED HOT CHILI™ MUMAK last week. The decisive factors were the positive outlook for AI memory solutions, favorable industry fundamentals, and an initially positive technical picture.
However, the positive development has already been accompanied by a significant price increase. Revolution Medicines therefore remains a company that should continue to be closely monitored.
Since then, the share price has weakened. The position is currently around 7.1% below its purchase price.
The upcoming quarterly results from Micron remain the next important test. Until then, the position requires patience and does not warrant a renewed award.
Mixed signals within the UMBRELLA Strategy
- Johnson & Johnson: approx. +8.6%
- Eli Lilly: approx. +3.3%
- Bayer: approx. +10.5%
- SpaceX: approx. +2.5%
- Palantir Technologies: approx. +0.3%
However, none of these companies currently combine a sufficiently strong new catalyst with favorable market sentiment and convincing technical momentum.
At the same time, MercadoLibre, Rheinmetall, Micron Technology, and TKMS are trading below their respective purchase prices. Their long-term investment theses continue to be monitored.
Key Takeaway
No RED HOT CHILI™ MUMAK will be awarded this week.
The combination of limited short-term catalysts, mixed market sentiment, and weaker technical signals currently prevents any company in the portfolio from achieving a sufficiently strong alignment across all five MUMAK® analysis categories.
Note
At any given time, there can only be one RED HOT CHILI™ MUMAK. In weeks where no company meets the required criteria, the award may remain unassigned.
The RED HOT CHILI™ MUMAK is an internal award of the MUMAK® UMBRELLA Strategy. It identifies the company that, at the time of publication, shows the highest alignment across the five MUMAK® analysis categories within our analysis universe.
Neither this award nor the decision not to award it constitutes investment advice or a recommendation to buy, hold, or sell. Investments are subject to risks and can lead to the complete loss of invested capital.
